{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:34:06Z","timestamp":1774877646831,"version":"3.50.1"},"reference-count":19,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2026,3,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Health care accounts for 4.6% of Canada's greenhouse gas (GHG) emissions, 25% of which comes from medications. Antimicrobials with high bioavailability offer no additional benefit when given intravenously, except when oral (PO) administration is not feasible. Intravenous (IV) formulations have a higher carbon footprint than their PO counterparts. IV-to-PO switch strategies benefit patients and the health care system by reducing line-related adverse events, nursing time, length of hospital stay, and costs and can also reduce carbon emissions. Our primary objective was to quantify IV use of bioequivalent antimicrobials when PO administration is feasible. Secondary objectives were to determine GHG emissions and antimicrobial costs associated with unnecessary IV use of bioequivalent antimicrobials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective, cross-sectional study of hospitalized adults who received IV azithromycin, ciprofloxacin, clindamycin, cotrimoxazole, fluconazole, levofloxacin, linezolid, metronidazole, moxifloxacin, or voriconazole at Vancouver General Hospital on five dates. We determined the proportion of patients receiving these antimicrobials who met criteria for PO administration. We also applied a life cycle assessment (LCA) to assess the GHG emissions of the antimicrobial drug delivery systems using OpenLCA with the Ecoinvent database. Using these data, we calculated the GHG emissions and costs associated with unnecessary IV use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 128 patients were identified. Seventy-eight (61%) met IV-to-PO switch criteria on the audit dates. Most eligible patients were admitted to general surgery, internal medicine, or critical care. The antimicrobial with the highest IV-to-PO switch eligibility was metronidazole (51%), most often prescribed for intra-abdominal infections. Over the five study dates, potential GHG savings were about 80,000 gCO\n                      <jats:sub>2<\/jats:sub>\n                      -eq. Potential annual cost savings were about $59,000.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Over 60% of patients receiving highly bioavailable IV antimicrobials were eligible for PO therapy, highlighting an opportunity to optimize prescribing. Promoting an IV-to-PO switch can improve patient outcomes and reduce environmental impact, supporting both patient-centred care and planetary health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3138\/jammi-2025-0029","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:39:18Z","timestamp":1774874358000},"page":"70-81","source":"Crossref","is-referenced-by-count":0,"title":["Using a planetary health lens to quantify intravenous use of bioequivalent antimicrobials when oral administration is feasible"],"prefix":"10.3138","volume":"11","author":[{"given":"Meghan","family":"MacLaren","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanne","family":"Thalakada","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British Columbia, Canada"},{"name":"ASPIRES, Vancouver Coastal Health, Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[{"name":"University of British Columbia Clean Energy Research Centre, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim TY","family":"Lau","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British Columbia, Canada"},{"name":"ASPIRES, Vancouver Coastal Health, Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salomeh","family":"Shajari","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British Columbia, Canada"},{"name":"ASPIRES, Vancouver Coastal Health, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotao","family":"Bi","sequence":"additional","affiliation":[{"name":"University of British Columbia Clean Energy Research Centre, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaqil","family":"Peermohamed","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British Columbia, Canada"},{"name":"ASPIRES, Vancouver Coastal Health, Vancouver, British Columbia, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","reference":[{"issue":"7","key":"r1","doi-asserted-by":"crossref","first-page":"e1002623","DOI":"10.1371\/journal.pmed.1002623","volume":"15","author":"Eckelman MJ","year":"2018","journal-title":"PLoS Med"},{"key":"r2","unstructured":"Vancouver Coastal Health. Climate change adaptation report: Vancouver Coastal Health. https:\/\/www2.gov.bc.ca\/assets\/gov\/environment\/climate-change\/cnar\/2023\/ha\/vancouver_coastal_health_2023_ccar.pdf (Accessed September 16, 2024)."},{"key":"r3","unstructured":"Centers for Disease Control and Prevention. Core elements of hospital antibiotic stewardship programs. https:\/\/www.cdc.gov\/antibiotic-use\/hcp\/core-elements\/index.html (Accessed September 16, 2024)."},{"issue":"1","key":"r4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0924-8579(02)00248-0","volume":"21","author":"Starakis I","year":"2003","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"r5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00151829-200403050-00006","volume":"3","author":"Zevros M","year":"2004","journal-title":"Treat Respir Med"},{"issue":"11","key":"r6","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/phar.2024","volume":"37","author":"Rieger K","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"2","key":"r7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4212\/cjhp.v75i2.3173","volume":"75","author":"Dulku M","year":"2022","journal-title":"Can J Hosp Pharm"},{"key":"r8","unstructured":"De Jaegher N. LCA comparison between oral and intravenous antibiotics: the ciprofloxacin case, 2024. https:\/\/thesis.dial.uclouvain.be\/server\/api\/core\/bitstreams\/38fd34e9-678f-4440-b3c9-edb7e5c7c015\/content (Accessed August 29, 2025)."},{"key":"r9","unstructured":"BC Health Authorities Pharmacy & Therapeutics Committee. Sequential antimicrobial therapy in adults \u2013 best practice recommendations. http:\/\/www.bccdc.ca\/Documents\/SBAR%20Sequential%20Antimicrobial%20Therapy%20Best%20Practice%20Recommendations.pdf (Accessed September 16, 2024)."},{"issue":"9","key":"r10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s11367-016-1087-8","volume":"21","author":"Wernet G","year":"2016","journal-title":"Int J Life Cycle Assess"},{"key":"r11","unstructured":"Marion County, Oregon. Energy from waste facility\u200b. https:\/\/www.co.marion.or.us\/PW\/ES\/disposal\/Pages\/mcwef.aspx (Accessed August 15, 2024)."},{"key":"r12","unstructured":"United States Environmental Protection Agency. Air pollution control technology fact sheet: thermal incinerator. https:\/\/www3.epa.gov\/ttnchie1\/mkb\/documents\/fthermal.pdf (Accessed August 20, 2024)."},{"key":"r13","unstructured":"The Engineering ToolBox. Solids\u2014specific heats. https:\/\/www.engineeringtoolbox.com\/specific-heat-solids-d_154.html (Accessed August 20, 2024)."},{"key":"r14","unstructured":"GridInfo. Plant summary information: Covanta Marion Inc. https:\/\/www.gridinfo.com\/plant\/covanta-marion-inc\/50630 (Accessed August 15, 2024)."},{"key":"r15","unstructured":"International Energy Agency. Fuel economy in major car markets: technology and policy drivers 2005-2017. https:\/\/www.iea.org\/reports\/fuel-economy-in-major-car-markets (Accessed August 27, 2025)."},{"issue":"1","key":"r16","first-page":"28","volume":"67","author":"Wong D","year":"2025","journal-title":"B C Med J"},{"issue":"8","key":"r17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/anae.15482","volume":"76","author":"Myo J","year":"2021","journal-title":"Anaesthesia"},{"issue":"15","key":"r18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jhin.2021.10.001","volume":"118","author":"Jamal H","year":"2021","journal-title":"J Hosp Infect"},{"issue":"1","key":"r19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10098-010-0289-1","volume":"13","author":"Fiksel J","year":"2011","journal-title":"Clean Technol Envir"}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/jammi-2025-0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:39:40Z","timestamp":1774874380000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/jammi-2025-0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3,27]]}},"alternative-id":["10.3138\/jammi-2025-0029"],"URL":"https:\/\/doi.org\/10.3138\/jammi-2025-0029","relation":{},"ISSN":["2371-0888"],"issn-type":[{"value":"2371-0888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}